Laura Chico
Stock Analyst at Wedbush
(2.23)
# 2,687
Out of 4,761 analysts
201
Total ratings
38.35%
Success rate
-1.7%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Reiterates: Neutral | $6 | $7.31 | -17.92% | 9 | Feb 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $157 → $147 | $120.69 | +21.80% | 9 | Feb 7, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $46 → $48 | $42.59 | +12.70% | 12 | Jan 13, 2025 | |
| SLDB Solid Biosciences | Initiates: Outperform | $16 | $5.78 | +176.82% | 1 | Dec 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $44 → $45 | $27.07 | +66.24% | 9 | Nov 8, 2024 | |
| VIGL Vigil Neuroscience | Maintains: Outperform | $23 → $24 | $3.03 | +692.08% | 8 | Nov 8, 2024 | |
| PEPG PepGen | Maintains: Outperform | $19 → $12 | $1.37 | +775.91% | 9 | Nov 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $30 → $38 | $28.58 | +32.96% | 7 | Nov 8, 2024 | |
| ANRO Alto Neuroscience | Downgrades: Neutral | $29 → $4 | $3.19 | +25.39% | 3 | Oct 23, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $17 → $25 | $21.98 | +13.74% | 9 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.19 | +589.66% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $140.64 | +45.76% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $48 | $74.49 | -35.56% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $6.81 | +223.05% | 8 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $1.40 | +185.71% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $41 | $27.52 | +48.98% | 13 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $39.73 | +23.33% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $23.67 | +52.09% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.22 | +65.88% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $20.73 | +25.42% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $5.06 | +117.39% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $16.27 | +158.14% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $8.33 | +104.08% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.37 | +1,629.96% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $16.49 | +87.99% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.75 | +1,358.89% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $0.62 | +1,195.55% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.91 | +1.83% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $68.25 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.61 | +210.56% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $36.91 | +302.33% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $8.18 | +8,701.96% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $21.54 | +1,199.91% | 1 | Apr 21, 2017 |
Sage Therapeutics
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $7.31
Upside: -17.92%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $120.69
Upside: +21.80%
Ultragenyx Pharmaceutical
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $42.59
Upside: +12.70%
Solid Biosciences
Dec 13, 2024
Initiates: Outperform
Price Target: $16
Current: $5.78
Upside: +176.82%
Edgewise Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $44 → $45
Current: $27.07
Upside: +66.24%
Vigil Neuroscience
Nov 8, 2024
Maintains: Outperform
Price Target: $23 → $24
Current: $3.03
Upside: +692.08%
PepGen
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.37
Upside: +775.91%
Vera Therapeutics
Nov 8, 2024
Maintains: Neutral
Price Target: $30 → $38
Current: $28.58
Upside: +32.96%
Alto Neuroscience
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $3.19
Upside: +25.39%
Travere Therapeutics
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $21.98
Upside: +13.74%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $3.19
Upside: +589.66%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $140.64
Upside: +45.76%
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $74.49
Upside: -35.56%
Aug 13, 2024
Reiterates: Outperform
Price Target: $22
Current: $6.81
Upside: +223.05%
Aug 13, 2024
Reiterates: Outperform
Price Target: $4
Current: $1.40
Upside: +185.71%
Aug 9, 2024
Maintains: Neutral
Price Target: $38 → $41
Current: $27.52
Upside: +48.98%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $39.73
Upside: +23.33%
Aug 9, 2024
Maintains: Outperform
Price Target: $38 → $36
Current: $23.67
Upside: +52.09%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.22
Upside: +65.88%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $20.73
Upside: +25.42%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $5.06
Upside: +117.39%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $16.27
Upside: +158.14%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $8.33
Upside: +104.08%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.37
Upside: +1,629.96%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $16.49
Upside: +87.99%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.75
Upside: +1,358.89%
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $0.62
Upside: +1,195.55%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.91
Upside: +1.83%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $68.25
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $1.61
Upside: +210.56%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $36.91
Upside: +302.33%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $8.18
Upside: +8,701.96%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $21.54
Upside: +1,199.91%